rxstatShortages › Capmatinib

Capmatinib (Tabrecta) shortage status

No current shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Capmatinib has no current shortage reported in Canada. No active reports are on file.

A targeted therapy used to treat certain types of lung cancer.

Products affected
0 / 1
Reports on file
1

Reports by product

Resolved
TABRECTA
150MG · TABLET · NOVARTIS PHARMACEUTICALS CANADA INC
DIN 02527391 · ended Jul 14, 2025 · Demand increase for the drug.

What's happening

There are no active shortage reports for Capmatinib.

Recent changes

Common questions

What is Capmatinib used for?

A targeted therapy used to treat certain types of lung cancer.

When will Capmatinib be back in stock in Canada?

Capmatinib has no active shortage; supply is normal per Health Canada reports.

Why is Capmatinib in shortage?

It isn't currently. Past reports and their reasons are listed above.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Related drugs

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.